Story
Wells Fargo Options Volume Surges on 4% Drop, Revealing Split Market View

Summary
Heavy options trading in Wells Fargo followed a sharp intraday stock decline, with a near-even split between bullish and bearish contracts signaling significant disagreement among investors on the bank's near-term direction.
A sharp intraday drop in Wells Fargo & Company (WFC) shares on Tuesday triggered a surge in options market activity, revealing a deeply divided sentiment among traders. The stock fell nearly 4% to trade around $83.13, prompting the exchange of nearly 85,000 options contracts in the first two hours of the session, according to data from Investing.com.
A Bifurcated Market
The most telling aspect of the trading activity was the near-perfect balance between bearish and bullish positions. Total volume was composed of 44,071 put contracts (bets on a price decline) and 40,863 call contracts (bets on a price increase). This tight split suggests that the sell-off did not create a one-sided panic, but rather a battlefield between traders with opposing views on the bank's future trajectory.
Adding to the uncertainty, 3-month implied volatility for the stock jumped 1.15 percentage points to 28.45%, signaling that the market is pricing in the potential for larger price swings in the coming months.
The Bullish Counter-Trade
Despite the stock's decline, the single largest transaction of the session was a distinctly bullish one. A trader or group of traders opened a massive bull call spread targeting a recovery by mid-October.
Ad- Trade Structure: The position involved buying 11,036 of the October 16, 2026 $89 calls and selling 11,035 of the $96 calls.
- New Conviction: The trade was almost entirely a new position, as prior open interest in the $89 strike was just 180 contracts, Investing.com data showed.
- Market Impact: For this bet to be profitable, WFC shares would need to rally over 7% from current levels to break even at $89. This sizable and freshly opened position indicates strong conviction from at least one large market participant that Tuesday's drop was overdone.
Defensive Hedging and Key Levels
On the other side of the ledger, bearish and defensive positioning remained robust. One notable structure was a June 2027 trade with a 2:1 put-to-call ratio, indicating a greater emphasis on downside protection. Furthermore, significant new volume flowed into the December 2026 $80 put, adding to an already massive open interest of over 65,000 contracts at that strike.
This activity reinforces the $80 level as a critical psychological and technical floor that many investors are watching. The stock's intraday price of $83.13 had already breached its first weekly support level of $83.95, with the next major technical support seen at $81.77.
Read next
More on Stocks
AutoZone Shares Jump as Strong Margins Outweigh Revenue Miss
The auto parts retailer reported fiscal fourth-quarter earnings that surpassed analyst expectations, driven by significant margin expansion, even as revenue fell short of forecasts for the fourth consecutive quarter.

Anthropic Launches Cheaper, Faster Claude 5.5 AI Model Ahead of Potential IPO
Anthropic has released its new flagship AI model, Claude Opus 5.5, which the company says is 40% cheaper and over 30% faster for enterprise use. The launch intensifies competition in the AI sector as the startup reportedly prepares for an initial public offering.

Bank of America Lifts Cybersecurity Price Targets on AI Threat Concerns
Bank of America has raised its price objectives for CrowdStrike, Okta, and SailPoint, citing growing investor recognition that artificial intelligence creates new security risks requiring significant investment. The cybersecurity sector has recently outperformed the broader market as the focus shifts to AI governance and threat mitigation.

AnaptysBio Stock Drops Despite Massive Q2 Earnings Beat as GSK Court Ruling Looms
AnaptysBio reported a significant earnings and revenue surprise for the second quarter, driven by strong Jemperli royalties. However, shares fell as investor attention remains fixed on the pending outcome of a key court case with partner GSK.